
-
Innate Pharma SA NasdaqGS:IPHA Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Location: 117, Avenue de Luminy, Bp 30191, Marseille, 13009, France | Website: https://www.innate-pharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
153M
Cash
80.77M
Avg Qtr Burn
-1.724M
Short % of Float
0.11%
Insider Ownership
0.00%
Institutional Own.
0.24%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LUMOXITI Details Leukemia, Cancer | Approved Quarterly sales | |
Monalizumab + durvalumab + oleclumab Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 3 Update | |
IPH6101 / SAR443579 Details Cancer, Relapsed/refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia | Phase 2 Data readout | |
Monalizumab (anti-NKG2A) Details Solid tumor/s, Cancer | Phase 2 Data readout | |
IPH5201 Details Lung cancer, Cancer, Non-small cell lung carcinoma | Phase 2 Data readout | |
Lacutamab (IPH4102) + GEMOX Details Cancer, Lymphoma, Peripheral T cell cancer | Phase 2 Data readout | |
Avdoralimab (IPH5401) Details COVID-19, Infectious disease | Phase 2 Update | |
Lacutamab (IPH4102) Details Lymphoma, Cancer, Mycosis fungoides | Phase 2 Update | |
Lacutamab (IPH4102) Details Lymphoma, Sezary syndrome, Cancer | Phase 2 Update | |
IPH6401 / SAR’514 Details Cancer, relapsed or refractory light chain amyloidosis, Multiple myeloma, Post-stroke recovery | Phase 1/2 Data readout | |
IPH6501 Details Cancer, Non-Hodgkin lymphoma | Phase 1/2 Update | |
Lacutamab (IPH4102) Details Cancer, Lymphoma, Peripheral T cell cancer | Phase 1b Data readout | |
IPH4502 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
IPH5301 (anti-CD73) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
Monalizumab (anti-NKG2A) Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer | Failed Discontinued | |
Avdoralimab (IPH5401) Details Bullous pemphigoid , Skin disease/disorder | Failed Discontinued |